Please Wait...

BioClinica Acquires Synowledge

Adds Capabilities in Pharmacovigilance and Regulatory technology, Data Analysis and Business Process Management

September 21, 2015

BioClinica®, Inc., a specialty clinical trials services and technology provider, today announced that it has acquired Synowledge to expand its offering into the growing drug safety and regulatory business process outsourcing market.  Headquartered in Miami, Synowledge specializes in pharmacovigilance, regulatory affairs and information technology services to support biopharmaceutical companies with recording, analyzing and reporting adverse drug events.

"This acquisition extends BioClinica's solutions into an important new area for our customers," said BioClinica President and Chief Executive Officer John Hubbard.  "Synowledge is a highly regarded provider that biopharmaceutical corporations trust to manage the critical process of monitoring and reporting adverse drug events.  Its capabilities complement our deep scientific expertise and technology-enabled services that support our customers in developing and bringing new drugs to market as safely and efficiently as possible."

Since its founding in 2006, Synowledge has grown rapidly to serve many of the world's leading pharmaceutical and biotechnology organizations.  The company offers pharmacovigilance services across all therapeutic areas and stages of drug development, including case processing, aggregate reporting, medical literature review, call center support and signal detection.  Synowledge employs a highly skilled global workforce of more than 500 people who provide customers with around-the-clock expertise and support remotely or onsite.  The company also offers information technology services for drug safety applications.

Sankesh Abbhi, who founded Synowledge, said, "We are very pleased to become part of BioClinica.  Our companies share a deep commitment to serving our customers and supporting their goals through highly specialized expertise and tailored solutions. Together, we offer customers a broader set of services and increased access to resources that support their overall drug development process."

Effective immediately, Mr. Abbhi will serve as senior vice president and head of global safety and regulatory solutions.  He will report to Mukhtar Ahmed, president of BioClinica's eClinical Solutions Division.

"Synowledge is a proven industry leader in the adoption of pharmacovigilance and regulatory technologies," said Mr. Ahmed. "With its depth of expertise in business process execution, data analysis and application-managed services, we will further extend our eClinical product and services portfolio so that we can provide our customers with a comprehensive offering that spans across the life sciences landscape."

About Synowledge
Synowledge is a specialized Pharmacovigilance, Regulatory Affairs and IT services provider that assists and enables small, medium and large life sciences organizations to satisfy their global regulatory requirements. The Synowledge team consists of highly qualified and skilled experts who are committed to helping companies meet and exceed the challenging demands of the R&D lifecycle. Our comprehensive outsourcing solutions cover all therapeutic areas and combine the unique strengths and knowledge of industry leading experts. Our commitment to quality allows us to deliver accurate, consistent, and robust solutions to the life sciences industry. Synowledge was founded in 2006 and is headquartered in Miami, Florida.  Synowledge has global offices in North America, Europe, India, and Japan. For more information, please visit http://www.synowledge.com.

About Bioclinica

Bioclinica is a global life science provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica's experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval. The company's offerings include medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments and budget forecasting; pharmacovigilance and trial management. The company's thousands of employees serve more than 500 pharmaceutical, biotechnology and device organizations – including all top 20 biopharmaceutical companies and leading CROs – through offices in North America, Europe, and Asia.

Learn more about Bioclinica at www.Bioclinica.com and in the Bioclinica Blog. Follow the latest company news and happenings on LinkedIn and Twitter.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Changes are a fact of life - and of #clinicaltrial design. But that doesn't mean planning and budgeting for your tr… https://t.co/BUPFjuIXOt
Bioclinica (Yesterday)
Bioclinica announced today that the company has contributed data to the primary efficacy endpoint in more than 200… https://t.co/8epFHqKFcL
Bioclinica (6 days ago)
No change order fees for new clients with our #RTSM platform means fewer hurdles as you race to study start. Ready… https://t.co/Z5AOtkWT3e
Bioclinica (2 weeks ago)
With over 25 years of experience in Cardiac Safety monitoring services, Bioclinica is a recognized global leader in… https://t.co/CMY48C4QVR
Bioclinica (2 weeks ago)
Bioclinica is an agile organization with more 2,300 colleagues around the globe - and growing! Learn more here.… https://t.co/oLPRURkhm7
Bioclinica (3 weeks ago)
Going to DIA Japan in Toyko? Meet our team at booth 47! https://t.co/X1jTu0UbUb https://t.co/vwKvUUbarp
Bioclinica (4 weeks ago)